Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial - Inzucchi, S E; Khunti, K; Fitchett, D H (J Clin Endocrinol Metab, 2020)